Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.55 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 11/20 | 0.38 |
| ▸ | GBA1 | P04062 | 7/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3106101 | 1.00 | SIGMAR1 (0.55) | SIGMAR1EBPCHRM2CHRM1GBA2 | |
| SCHEMBL4599654 | 0.98 | SIGMAR1 (0.56) | SIGMAR1EBPCHRM2CHRM1GBA2 | |
| SCHEMBL4599655 | 0.98 | SIGMAR1 (0.56) | SIGMAR1EBPCHRM2CHRM1GBA2 | |
| SCHEMBL3100817 | 0.98 | SIGMAR1 (0.56) | SIGMAR1EBPCHRM2CHRM1GBA2 | |
| SCHEMBL3090051 | 0.93 | SIGMAR1 (0.58) | SIGMAR1CHRM2CHRM1GBA2GBA1 | |
| SCHEMBL24965969 | 0.85 | SIGMAR1 (0.53) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL14135342 | 0.85 | SIGMAR1 (0.53) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL15217044 | 0.85 | SIGMAR1 (0.53) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL3100760 | 0.85 | SIGMAR1 (0.53) | SIGMAR1CHRM2CHRM1GAA | |
| SCHEMBL5691697 | 0.80 | EBP (0.52) | SIGMAR1EBPGBA2GBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2005-04-07 | — | — | US | disclosed |
| EP-1456186-A1 | NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A SB 2 /SB PHOSPHOLIPASE OF GROUP II | Yang Ji Chemical Company Ltd. (KR) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003048139-A1 | NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A2 PHOSPHOLIPASE OF GROUP II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | AMY2A, PNLIP, IAPP | SIGMAR1 2516/4885EBP 1170/4885CHRM2 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.